A Phase I Surrogate Endpoint Trial of SU6668 in Patients With Incurable Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2011
At a glance
- Drugs Orantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 07 Sep 2006 Status change
- 27 Sep 2005 New trial record.